TriangleNCT03081689 · OUTCOME
Progression Free Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- percentage of participants
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- at 24 months from the first dose of neoadjuvant treatment
What was measured
The progression free survival is the percentage of the patients without disease progression
Groups in this outcome
Arm 1
Nivolumab 360 mg IV Q3W + Paclitaxel 200mg/m2 + Carboplatin AUC 6 IV Q3W in resectable stage IIIA N2-NSCLC adult patients followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months Nivolumab 360 mg: Nivolumab 360 mg IV Q3W + Followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months Paclitaxel 200mg/m2: Paclitaxel 200mg/m2 IV Q3W Carboplatin AUC 6: Carboplatin AUC 6 IV Q3W
| Group | Source count |
|---|---|
| Arm 1 | 46 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Arm 1 | 77.1 | Not reported | 59.9 | 87.7 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 59.9
- upper Limit
- 87.7
- value
- 77.1
- denoms
- counts
- group Id
- OG000
- value
- 46
- units
- Participants
- description
- The progression free survival is the percentage of the patients without disease progression
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Nivolumab 360 mg IV Q3W + Paclitaxel 200mg/m2 + Carboplatin AUC 6 IV Q3W in resectable stage IIIA N2-NSCLC adult patients followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months Nivolumab 360 mg: Nivolumab 360 mg IV Q3W + Followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months Paclitaxel 200mg/m2: Paclitaxel 200mg/m2 IV Q3W Carboplatin AUC 6: Carboplatin AUC 6 IV Q3W
- id
- OG000
- title
- Arm 1
- param Type
- NUMBER
- reporting Status
- POSTED
- time Frame
- at 24 months from the first dose of neoadjuvant treatment
- title
- Progression Free Survival
- type
- PRIMARY
- unit Of Measure
- percentage of participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice